Literature DB >> 16200345

Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model.

Jean-François Mineo1, Anne Bordron, Isabelle Quintin-Roué, Quintin-Roué Isabelle, Claude-Alain Maurage, Virginie Buhé, Buhé Virginie, Séverine Loisel, Loisel Séverine, François Dubois, Serge Blond, Christian Berthou.   

Abstract

Glioblastoma multiform (GBM) remains the most devastating primary tumour in neuro-oncology. Human Epithelial Receptor Type 2 (HER2) is a transmembrane tyrosine/kinase receptor that is important for cancer growth. HER2 is not expressed in adult glial cells, but its expression increases with the degree of astrocytomas anaplasia. We have recently demonstrated the ability of anti-HER2 antibodies to induce in vitro apoptosis GBM cell lines; this ability is correlated to HER2 density. A decreasing of tyrosine/kinase receptors density during in vitro culture was reported. No information exists about the variation of HER2 expression after in vivo implantation. For that, the two cell lines in vitro tested (U251MG, A172) were in vivo implanted. We established a U251MG in vivo model in balb/c nude mice showing an important increasing of HER2 density. The HER2 density is correlated to anti-HER2 antibody efficiency so this model will be useful for the evaluation of in vivo anti-HER2 antibody treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16200345     DOI: 10.1007/s11060-005-6875-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

Authors:  Michael P DiGiovanna; David F Stern; Susan M Edgerton; Steve G Whalen; Dan Moore; Ann D Thor
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

2.  Heregulins and the ErbB-2/3/4 receptors in gliomas.

Authors:  M Westphal; L Meima; E Szonyi; J Lofgren; H Meissner; W Hamel; K Nikolics; M X Sliwkowski
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

3.  [Glioblastomas: clinical study and search for prognostic factors].

Authors:  J-F Mineo; I Quintin-Roue; B Lucas; V Buburusan; G Besson
Journal:  Neurochirurgie       Date:  2002-12       Impact factor: 1.553

4.  Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.

Authors:  Scott E Forseen; Anil Potti; Vijay Koka; Michael Koch; Genise Fraiman; Ralph Levitt
Journal:  Anticancer Res       Date:  2002 May-Jun       Impact factor: 2.480

5.  Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

Authors:  G D Lewis; J A Lofgren; A E McMurtrey; A Nuijens; B M Fendly; K D Bauer; M X Sliwkowski
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

Review 6.  Properties of human malignant glioma cells in vitro.

Authors:  J Pontén; B Westermark
Journal:  Med Biol       Date:  1978-08

7.  Expression of HER2 and its association with AP-2 in breast cancer.

Authors:  J Pellikainen; A Naukkarinen; K Ropponen; J Rummukainen; V Kataja; J Kellokoski; M Eskelinen; V-M Kosma
Journal:  Eur J Cancer       Date:  2004-07       Impact factor: 9.162

8.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.

Authors:  D Graus-Porta; R R Beerli; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

9.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

Authors:  M F Press; C Cordon-Cardo; D J Slamon
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

10.  Brain microglia constitutively express beta-2 integrins.

Authors:  H Akiyama; P L McGeer
Journal:  J Neuroimmunol       Date:  1990-11       Impact factor: 3.478

View more
  3 in total

1.  Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Swetlana Rot; Jacqueline Kessler; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

2.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

Review 3.  New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.

Authors:  Jan Korbecki; Izabela Gutowska; Ireneusz Kojder; Dariusz Jeżewski; Marta Goschorska; Agnieszka Łukomska; Anna Lubkowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Oncotarget       Date:  2018-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.